Insider Brief
- Thesis Care raised $45 million in a Series A led by Oak HC/FT, bringing total funding to $60 million as it expands its AI-powered clinical care platform.
- The company combines AI agents with clinician oversight to automate care management and clinical workflows, increasing capacity without disrupting existing healthcare systems.
- With partnerships across major provider organizations, Thesis plans to scale its platform, expand its agent capabilities, and grow adoption across health systems and care teams.
PRESS RELEASE — Thesis Care (formerly Trovo Health), the AI-powered care team platform for scalable clinical capacity, announced $45 million in Series A funding led by Oak HC/FT, with participation from CRV, and additional support from Black Opal Ventures and experienced C-level healthcare technology angel investors. This brings the total funding for Thesis to $60 million.
With this announcement, the company is also unveiling its new name, Thesis Care, to reflect the evolution of its platform. Thesis deploys AI agents backed by expert clinicians to take on high-impact clinical operations and care management work for healthcare organizations.
The platform is powered by AI that understands clinical context to deliver personalized patient engagement and complete workflow actions, all while knowing when and how to engage Thesis’s team of clinical experts-in-the-loop. Because Thesis completes tasks end-to-end and delivers the result, it does not require staff or providers to learn a new tool and keeps existing workflows intact.
“2025 was a defining year for Thesis as we moved from design partnerships into a clear commercial trajectory and growing customer base,” said Niren Gandra, M.D., CEO and co-founder of Thesis Care. “We’ve proven that we can extend clinical capacity and allow our customers to do more for patients at a scale that has historically been impossible. Now, we’re ready to bring that to every healthcare organization that needs it.”
Thesis’s partnerships cover thousands of providers and include large provider organizations across primary and specialty care. Partners include US Heart & Vascular, Essen Health Care, Springfield Clinic, Unio Health Partners, and Allied Digestive Health. The company is currently expanding into partnerships with health systems and health plan care teams.
“Thesis lets us deliver better care at scale — without the operational lift you’d expect,” said Shaivali Shah, SVP of Operations at Allied Digestive Health. “It takes real work off our staff’s plates, patients show up prepared, and care gaps get closed. What sets Thesis apart is the human care team behind the agents — that combination of automation and human judgment is what takes patient care to another level. The ROI speaks for itself.”
“As we scale USHV, we look for partners who can deliver on innovation and execution,” said Mike Plantz, Senior Vice President of Revenue Operations at U.S. Heart & Vascular, a leading MSO for more than 300 cardiovascular providers. “Thesis’s combination of AI agents and care team experts allowed us to deploy solutions quickly with minimal internal lift, resulting in a tangible reduction in administrative burden and strengthened practice support.”
With this funding, the company plans to accelerate commercial expansion, deepen the build of the unified technology platform, and broaden its suite of care team agents.
“Thesis has developed a fundamentally unique platform that addresses clinically deep, complex workflows,” said Andrew Adams, Co-Founder & Managing Partner at Oak HC/FT. “We are proud to continue our partnership with the Thesis team as they build the infrastructure for the future of scalable care delivery.”
About Thesis Care
Thesis Care is an AI-powered care team platform for scalable clinical capacity. The company combines AI agents with expert clinicians to take on high-impact clinical operations and care management activities for healthcare organizations. Founded in 2024 by Niren Gandra and Aditya Pandyaram, the company is headquartered in New York, NY and backed by investors including Oak HC/FT, CRV, and Black Opal Ventures. Learn more at thesis.care.
About Oak HC/FT
Oak HC/FT is a venture and growth equity firm specializing in investments in fintech and healthcare. Using partnership as a foundation, Oak HC/FT guides companies and founders at every stage, from seed to growth, to create businesses that make a measurable and lasting impact. Founded in 2014, Oak HC/FT has invested in 120 portfolio companies and has more than $7 billion in assets under management. Oak HC/FT is headquartered in Stamford, CT, with an office in San Francisco, CA. Follow Oak HC/FT on LinkedIn and X and learn more at www.oakhcft.com.
Contacts
Jackie Kahn
jackie@oakhcft.com
